Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BVXP.L
Strong BuyFull HouseREMOVEBioventix PLC · Healthcare · United Kingdom · $122M · Avg Vol: $219K/d
While Bioventix has historically exhibited quality metrics, recent performance has been lacklustre. Without a clear macro-driven inflection point or significant thematic tailwind to reignite growth, it fails our 'Druckenmiller Lens' criteria for an asymmetric opportunity.
COMPANY DESCRIPTION
Bioventix PLC develops and manufactures high-affinity sheep monoclonal antibodies (SMAs) for use in clinical diagnostics. The company possesses a powerful economic moat through proprietary cell lines that produce antibodies integrated into global, long-term diagnostic platforms. It is a high-margin, cash-generative biotechnology company with a highly defensive royalty-based business model.
FINANCIAL SUMMARY (GBP)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.7M | 12.8M | 13.6M | 13.1M | 3.8% | 12.5M | 12.5M | -4.7% |
| EPS (GBp) | 147.32 | 160.63 | 15,512 | 145.27 | -0.5% | 140.03 | 137.88 | -5.1% |
| Shares | 5.2M | 5.2M | 5.2M | 5.2M | +0.3% | 5.2M | — | — |
| Debt | — | — | — | — | — | — | — | — |
| Equity | 11.8M | 12.1M | 12.0M | 11.6M | -0.8% | — | — | — |
| Op CF | 7.6M | 7.8M | 8.3M | 7.0M | -2.4% | 7.8M | — | — |
| Inv CF | -7.0K | 90.5K | 0.2M | 0.2M | — | — | — | — |
| Fin CF | -7.9M | -8.3M | -8.2M | -8.1M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BVXP.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BVXP.L | Bioventix PLC(you) | $122M | 99 | Strong Buy |
| POLB.L | Poolbeg Pharma PLC | $89M | 26 | Sell |
| AREC.L | Arecor Therapeutics plc | $38M | 42 | Hold |
| SAR.L | Sareum Holdings plc | $63M | 21 | Sell |
| 4BB.L | 4basebio PLC | $110M | 9 | Strong Sell |
| GNS.L | Genus plc | $2.1B | 62 | Hold |
| AUTL | Autolus Therapeutics plc | $623M | 35 | Hold |
| SCLP.L | Scancell Holdings plc | $141M | 3 | Strong Sell |
| TLSA | Tiziana Life Sciences Ltd | $129M | 1 | Strong Sell |
| OKYO | OKYO Pharma Limited | $88M | 7 | Strong Sell |
Peer medians: ROE -4.1% · P/E 25.0x · Gross margin 55.3%